Selected research
Industry Research
Peptide Drug Conjugate Industry Research Report 2026
Market perspective
The global Peptide Drug Conjugate market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Peptide Drug Conjugate is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Peptide Drug Conjugate is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Peptide Drug Conjugate is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Peptide Drug Conjugate include Zhongshan Laibo Ruichen Biopharmaceutical, XINOGEN (HONG KONG) PHARMA, Tianjin Conjustar Biotechnology, Lumosa Therapeutics, Shanghai Pharmaceuticals, Shanghai Huiyong Pharmaceutical, Gaorui Yaoye(Beijing)Technologies, BrightGene Bio-Medical Technology and Beijing Shenogen Pharma Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Peptide Drug Conjugate market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Drug Conjugate Market by Company
Zhongshan Laibo Ruichen Biopharmaceutical
XINOGEN (HONG KONG) PHARMA
Tianjin Conjustar Biotechnology
Lumosa Therapeutics
Shanghai Pharmaceuticals
Shanghai Huiyong Pharmaceutical
Gaorui Yaoye(Beijing)Technologies
BrightGene Bio-Medical Technology
Beijing Shenogen Pharma Group
Theratechnologies
Cybrexa Therapeutics
Bicycle Therapeutics
Peptide Drug Conjugate Segment by Type
Cell Targeting Peptides (CTP)
Cell-penetrating Peptides (CPP)
Others
Peptide Drug Conjugate Segment by Application
Breast Cancer
Pancreatic Cancer
Others
Peptide Drug Conjugate Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Drug Conjugate market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Drug Conjugate and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Drug Conjugate.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide Drug Conjugate manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide Drug Conjugate by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide Drug Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cell Targeting Peptides (CTP)
- Cell-penetrating Peptides (CPP)
- Others
Applications
- Breast Cancer
- Pancreatic Cancer
- Others
Companies covered
- Zhongshan Laibo Ruichen Biopharmaceutical
- XINOGEN (HONG KONG) PHARMA
- Tianjin Conjustar Biotechnology
- Lumosa Therapeutics
- Shanghai Pharmaceuticals
- Shanghai Huiyong Pharmaceutical
- Gaorui Yaoye(Beijing)Technologies
- BrightGene Bio-Medical Technology
- Beijing Shenogen Pharma Group
- Theratechnologies
- Cybrexa Therapeutics
- Bicycle Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide Drug Conjugate Market Size (2021-2032)
- 2.2.2 Global Peptide Drug Conjugate Sales (2021-2032)
- 2.2.3 Global Peptide Drug Conjugate Market Average Price (2021-2032)
- 2.3 Peptide Drug Conjugate by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cell Targeting Peptides (CTP)
- 2.3.3 Cell-penetrating Peptides (CPP)
- 2.3.4 Others
- 2.4 Peptide Drug Conjugate by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Pancreatic Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide Drug Conjugate Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide Drug Conjugate Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Peptide Drug Conjugate Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide Drug Conjugate Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide Drug Conjugate Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide Drug Conjugate, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide Drug Conjugate, Product Type & Application
- 3.8 Global Manufacturers of Peptide Drug Conjugate, Established Date
- 3.9 Global Peptide Drug Conjugate Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhongshan Laibo Ruichen Biopharmaceutical
- 4.1.1 Zhongshan Laibo Ruichen Biopharmaceutical Company Information
- 4.1.2 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
- 4.1.3 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Portfolio
- 4.1.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
- 4.2 XINOGEN (HONG KONG) PHARMA
- 4.2.1 XINOGEN (HONG KONG) PHARMA Company Information
- 4.2.2 XINOGEN (HONG KONG) PHARMA Business Overview
- 4.2.3 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Portfolio
- 4.2.5 XINOGEN (HONG KONG) PHARMA Recent Developments
- 4.3 Tianjin Conjustar Biotechnology
- 4.3.1 Tianjin Conjustar Biotechnology Company Information
- 4.3.2 Tianjin Conjustar Biotechnology Business Overview
- 4.3.3 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Portfolio
- 4.3.5 Tianjin Conjustar Biotechnology Recent Developments
- 4.4 Lumosa Therapeutics
- 4.4.1 Lumosa Therapeutics Company Information
- 4.4.2 Lumosa Therapeutics Business Overview
- 4.4.3 Lumosa Therapeutics Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lumosa Therapeutics Peptide Drug Conjugate Product Portfolio
- 4.4.5 Lumosa Therapeutics Recent Developments
- 4.5 Shanghai Pharmaceuticals
- 4.5.1 Shanghai Pharmaceuticals Company Information
- 4.5.2 Shanghai Pharmaceuticals Business Overview
- 4.5.3 Shanghai Pharmaceuticals Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Portfolio
- 4.5.5 Shanghai Pharmaceuticals Recent Developments
- 4.6 Shanghai Huiyong Pharmaceutical
- 4.6.1 Shanghai Huiyong Pharmaceutical Company Information
- 4.6.2 Shanghai Huiyong Pharmaceutical Business Overview
- 4.6.3 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Portfolio
- 4.6.5 Shanghai Huiyong Pharmaceutical Recent Developments
- 4.7 Gaorui Yaoye(Beijing)Technologies
- 4.7.1 Gaorui Yaoye(Beijing)Technologies Company Information
- 4.7.2 Gaorui Yaoye(Beijing)Technologies Business Overview
- 4.7.3 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Portfolio
- 4.7.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
- 4.8 BrightGene Bio-Medical Technology
- 4.8.1 BrightGene Bio-Medical Technology Company Information
- 4.8.2 BrightGene Bio-Medical Technology Business Overview
- 4.8.3 BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Portfolio
- 4.8.5 BrightGene Bio-Medical Technology Recent Developments
- 4.9 Beijing Shenogen Pharma Group
- 4.9.1 Beijing Shenogen Pharma Group Company Information
- 4.9.2 Beijing Shenogen Pharma Group Business Overview
- 4.9.3 Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Portfolio
- 4.9.5 Beijing Shenogen Pharma Group Recent Developments
- 4.10 Theratechnologies
- 4.10.1 Theratechnologies Company Information
- 4.10.2 Theratechnologies Business Overview
- 4.10.3 Theratechnologies Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Theratechnologies Peptide Drug Conjugate Product Portfolio
- 4.10.5 Theratechnologies Recent Developments
- 4.11 Cybrexa Therapeutics
- 4.11.1 Cybrexa Therapeutics Company Information
- 4.11.2 Cybrexa Therapeutics Business Overview
- 4.11.3 Cybrexa Therapeutics Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cybrexa Therapeutics Peptide Drug Conjugate Product Portfolio
- 4.11.5 Cybrexa Therapeutics Recent Developments
- 4.12 Bicycle Therapeutics
- 4.12.1 Bicycle Therapeutics Company Information
- 4.12.2 Bicycle Therapeutics Business Overview
- 4.12.3 Bicycle Therapeutics Peptide Drug Conjugate Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Bicycle Therapeutics Peptide Drug Conjugate Product Portfolio
- 4.12.5 Bicycle Therapeutics Recent Developments
5 Global Peptide Drug Conjugate Market Scenario by Region
- 5.1 Global Peptide Drug Conjugate Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide Drug Conjugate Sales by Region: 2021-2032
- 5.2.1 Global Peptide Drug Conjugate Sales by Region: 2021-2026
- 5.2.2 Global Peptide Drug Conjugate Sales by Region: 2027-2032
- 5.3 Global Peptide Drug Conjugate Revenue by Region: 2021-2032
- 5.3.1 Global Peptide Drug Conjugate Revenue by Region: 2021-2026
- 5.3.2 Global Peptide Drug Conjugate Revenue by Region: 2027-2032
- 5.4 North America Peptide Drug Conjugate Market Facts & Figures by Country
- 5.4.1 North America Peptide Drug Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide Drug Conjugate Sales by Country (2021-2032)
- 5.4.3 North America Peptide Drug Conjugate Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Peptide Drug Conjugate Market Facts & Figures by Country
- 5.5.1 Europe Peptide Drug Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide Drug Conjugate Sales by Country (2021-2032)
- 5.5.3 Europe Peptide Drug Conjugate Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Peptide Drug Conjugate Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide Drug Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide Drug Conjugate Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide Drug Conjugate Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide Drug Conjugate Market Facts & Figures by Country
- 5.7.1 South America Peptide Drug Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide Drug Conjugate Sales by Country (2021-2032)
- 5.7.3 South America Peptide Drug Conjugate Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Peptide Drug Conjugate Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide Drug Conjugate Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide Drug Conjugate Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide Drug Conjugate Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Peptide Drug Conjugate Sales by Type (2021-2032)
- 6.1.1 Global Peptide Drug Conjugate Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Peptide Drug Conjugate Sales Market Share by Type (2021-2032)
- 6.2 Global Peptide Drug Conjugate Revenue by Type (2021-2032)
- 6.2.1 Global Peptide Drug Conjugate Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide Drug Conjugate Revenue Market Share by Type (2021-2032)
- 6.3 Global Peptide Drug Conjugate Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Peptide Drug Conjugate Sales by Application (2021-2032)
- 7.1.1 Global Peptide Drug Conjugate Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Peptide Drug Conjugate Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide Drug Conjugate Revenue by Application (2021-2032)
- 7.2.1 Global Peptide Drug Conjugate Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide Drug Conjugate Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide Drug Conjugate Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide Drug Conjugate Value Chain Analysis
- 8.1.1 Peptide Drug Conjugate Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide Drug Conjugate Production Mode & Process
- 8.2 Peptide Drug Conjugate Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide Drug Conjugate Distributors
- 8.2.3 Peptide Drug Conjugate Customers
9 Global Peptide Drug Conjugate Analyzing Market Dynamics
- 9.1 Peptide Drug Conjugate Industry Trends
- 9.2 Peptide Drug Conjugate Industry Drivers
- 9.3 Peptide Drug Conjugate Industry Opportunities and Challenges
- 9.4 Peptide Drug Conjugate Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst